Previously recorded as Janssen-Cilag S.A. (to 2010)
458 patents currently held
168 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
4 more records may belong here and await a decision; they are not counted.
The next US patent term in the Janssen Pharmaceutica N.V. portfolio ends in Mar 2027, and more of its terms end in 2037 (65) than in any other year. from the record
Of the 168 now held by other companies, 24 were conveyed to Astex Therapeutics Ltd. in the filing they arrived in, and 144 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
79
Ending by 2030
Mar 2027
Next term end
321
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Jun 2031 · High confidence
Also notable
Ends Jul 2035 · Medium confidence
Also notable
Ends Feb 2031 · Medium confidence
Also notable
Ends Sep 2036 · High confidence
Also notable
Ends Oct 2027 · High confidence
Also notable
Ends Jul 2037 · High confidence
Also notable
Ends Sep 2034 · High confidence
Also notable
Ends Jan 2039 · High confidence
Treatment of Sleep-Wake Disorders
US 8,440,715
The most cited patent in this portfolio, cited by 82 later US patents, top 10% of utility patents granted in 2013 in our data. Protection runs to 2031.
Anti-Vista Antibodies and Fragments
US 11,242,392
Cited by 15 later US patents, top 10% of utility patents granted in 2022 in our data. Protection runs to 2035.
Novel Compounds as Opioid Receptor Modulators
US 7,741,356
Cited by 66 later US patents, top 25% of utility patents granted in 2010 in our data, and renewed at 2 of 3 maintenance windows. Protection runs to 2031. A terminal disclaimer caps this term to an earlier patent's.
Novel 6-6 Bicyclic Aromatic Ring Substituted Nucleoside Analogues for Use as PRMT5 Inhibitors
US 10,653,711
Cited by 24 later US patents, top 10% of utility patents granted in 2020 in our data. Protection runs to 2036.
Sulfonylamino-Derivatives as Novel Inhibitors of Histone Deacetylase
US 7,767,679
Cited by 81 later US patents, top 10% of utility patents granted in 2010 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2027.
Method of Treating Prostate Cancer
US 11,207,311
Cited by 10 later US patents, top 25% of utility patents granted in 2021 in our data. Protection runs to 2037.
Intranasal Drug Delivery Device
US D860,435
Cited by 30 later US patents, top 25% of design patents granted in 2019 in our data. Protection runs to 2034.
System and Method for Healthcare Security and Interoperability
US 10,541,807
Cited by 13 later US patents, top 25% of utility patents granted in 2020 in our data. Protection runs to 2039.
Formerly held, still cited
Notable
Ends Dec 2033 · High confidence
The most cited patent in this portfolio, cited by 111 later US patents, top 5% of utility patents granted in 2016 in our data. Protection runs to 2033.
conveyed to Janssen Pharmaceuticals, Inc.
Also notable
Ends Nov 2035 · High confidence
Cited by 42 later US patents, top 5% of utility patents granted in 2019 in our data, and renewed at 2 of 3 maintenance windows. Protection runs to 2035.
now held by Janssen Pharmaceuticals N.V.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 4 fees due Nov 23 to 26, 2026 · next Nov 23
- 9 fees due Dec 11 to 30, 2026 · next Dec 11
- 13 fees due Jan 4 to 30, 2027 · next Jan 4
- 8 fees due Feb 6 to 25, 2027 · next Feb 6
- 4 fees due Mar 1 to 26, 2027 · next Mar 1
- 6 fees due Apr 1 to 30, 2027 · next Apr 1
- 13 fees due May 3 to 28, 2027 · next May 3
- 8 fees due Jun 12 to 30, 2027 · next Jun 12
- 7 fees due Jul 7 to 30, 2027 · next Jul 7
- 6 fees due Aug 6 to 18, 2027 · next Aug 6
- 6 fees due Sep 1 to 17, 2027 · next Sep 1
- 9 fees due Oct 2 to 30, 2027 · next Oct 2
- 9 fees due Nov 5 to 21, 2027 · next Nov 5
Recent changes
- Oct 26Assignment recorded on 1 record: Johnson & Johnson and 2 others to Janssen Pharmaceutica N.V. Recorded Oct 26, 2026, executed Apr 14, 2025. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76504, frame 646.
- Oct 21Assignment recorded on 1 record: Janssen Research & Development, LLC to Janssen Pharmaceutica N.V. Recorded Oct 21, 2026, executed Oct 15, 2026. Conveyance as recorded: Assignment of Assignor's Interest. A recorded assignment is a filed document, not a statement of current ownership. Reel 76450, frame 293.
- 12 of the patents on this record were granted since Aug 24, 2026
- 32 terms have ended since Aug 24, 2026
- Oct 30 US 10,112,949 6,7-Dihydropyrazolo[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS · lapsed on the fee record
- Oct 24 US 9,751,860 PIPERIDIN-4YL-PYRIDAZIN-3-Ylamine Derivatives as Fast Dissociating Dopamine 2 Receptor Antagonists · term ended
- Oct 23 US 7,432,343 Diagnostic Application of Mail · term ended
- Oct 23 US 10,106,553 Substituted Benzothiophenyl Derivatives as GPR40 Agonists for the Treatment of Type II Diabetes · lapsed on the fee record
- Oct 23 US 10,106,542 Substituted 6,7-Dihydropyrazolo[1,5-a]pyrazines as Negative Allosteric Modulators of MGLUR2 Receptors · lapsed on the fee record
- Oct 21 US 8,865,705 Benzimidazole Respiratory Syncytial Virus Inhibitors · lapsed on the fee record
- Oct 20 US 10,072,088 Anti-BCMA Antibodies and Uses Thereof · surrendered on reissue
- Oct 16 US 10,100,035 Substituted 2-[3-(1-Methyl-PIPERIDIN-4-YL)-PROPYLAMINO]-PYRIMIDINE-5-Carboxylic Acids and Amides and Methods of Making the Same · lapsed on the fee record
- Oct 14 US 8,859,602 Inhibitors of C-Fms Kinase · lapsed on the fee record
- Oct 14 US 8,859,575 BENZOIMIDAZOL-2-YL Pyrimidine Modulators of the Histamine H4 Receptor · lapsed on the fee record
- Oct 14 US 8,859,543 IMIDAZO[1,2-a]PYRAZINE DERIVATIVES AND THEIR USE FOR THE PREVENTION OR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC AND METABOLIC DISORDERS AND DISEASES · lapsed on the fee record
- Oct 7 US 8,853,418 Cyclopentylpyrazoles as N-Type Calcium Channel Blockers · lapsed on the fee record
- Oct 7 US 8,853,406 Substituted Phenylenediamines as Inhibitors of the Interaction Between MDM2 and P53 · lapsed on the fee record
- Oct 4 US 11,459,336 Pyrazine Carbamates and Their Use as GLUN2B Receptor Modulators · lapsed on the fee record
- Oct 2 US 10,087,187 Imidazopyridazine Derivatives as PI3KB Inhibitors · lapsed on the fee record
What they patent
The largest of its 321 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,738,649 | Tetrahydro-Pyrimidoazepines as Modulators of TRPV1 In force · Medium confidence | In force | Medium confidence | |
| US 8,895,584 | Inhibitors of C-Fms Kinase In force · Medium confidence | In force | Medium confidence | |
| US 8,933,091 | Method of Inhibiting C-Kit Kinase In force · Medium confidence | In force | Medium confidence | |
| US 7,776,882 | 2-Amino-3,4-Dihydro-QUINOLINE Derivatives Useful as Inhibitors of Beta-Secretase (BACE) In force · High confidence | In force | High confidence | |
| US 9,422,293 | Tetrahydro-Pyrimidoazepines as Modulators of TRPV1 In force · Low confidence | In force | Low confidence | |
| US 7,678,786 | Benzoazepin-Oxy-Acetic Acid Derivatives as Ppar-Delta Agonists Used for the Increase of Hdl-C, Lower Ldl-C and Lower Cholesterol In force · High confidence | In force | High confidence | |
| US 7,893,058 | Imidazolopyrazine Compounds Useful for the Treatment of Degenerative and Inflammatory Diseases In force · High confidence | In force | High confidence | |
| US 7,767,679 | Sulfonylamino-Derivatives as Novel Inhibitors of Histone Deacetylase In force · High confidence | In force | High confidence | |
| US 7,786,158 | Novel Compounds as Opioid Receptor Modulators In force · Medium confidence | In force | Medium confidence | |
| US 8,940,743 | PIPERIDIN-4-YL-PYRIDAZIN-3-Ylamine Derivatives as Fast Dissociating Dopamine 2 Receptor Antagonists In force · High confidence | In force | High confidence |
Also on record, not counted in the 458: 168 patents in force now held by others · 505 patents ended · 235 applications pending · 456 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.